T
Thomas Pabst
Researcher at University of Bern
Publications - 294
Citations - 10776
Thomas Pabst is an academic researcher from University of Bern. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 47, co-authored 250 publications receiving 8696 citations. Previous affiliations of Thomas Pabst include University Hospital of Bern & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg,Gert J. Ossenkoppele,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Johan Maertens,Mojca Jongen-Lavrencic,Marie von Lilienfeld-Toal,Bart J. Biemond,Edo Vellenga,Marinus van Marwijk Kooy,Leo F. Verdonck,Joachim Beck,Hartmut Döhner,Alois Gratwohl,Thomas Pabst,Gregor Verhoef +18 more
TL;DR: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional doses, without additional toxic effects.
Journal ArticleDOI
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mojca Jongen-Lavrencic,Tim Grob,Diana Hanekamp,François G. Kavelaars,Adil Al Hinai,Annelieke Zeilemaker,Claudia A.J. Erpelinck-Verschueren,Patrycja L Gradowska,Rosa Meijer,Jacqueline Cloos,Bart J. Biemond,Carlos Graux,Marinus van Marwijk Kooy,Markus G. Manz,Thomas Pabst,Jakob Passweg,Violaine Havelange,Gert J. Ossenkoppele,Mathijs A. Sanders,Gerrit Jan Schuurhuis,Bob Löwenberg,Peter J. M. Valk +21 more
TL;DR: The detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates, but the detection of persistent mutations that are associated with clonal hematopoiesis did not have such prognosticvalue within a 4‐year time frame.
Journal ArticleDOI
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn,Wim L.J. van Putten,Angèle Kelder,Vincent H.J. van der Velden,Rik A. Brooimans,Thomas Pabst,Johan Maertens,Nancy Boeckx,Georgine E. de Greef,Peter J. M. Valk,Frank Preijers,Peter C. Huijgens,Angelika M. Dräger,Urs Schanz,Mojca Jongen-Lavrecic,Bart J. Biemond,Jakob Passweg,Michel van Gelder,P. W. Wijermans,Carlos Graux,Mario Bargetzi,Marie-Cecile Legdeur,Jürgen Kuball,Okke de Weerdt,Yves Chalandon,Urs Hess,Leo F. Verdonck,Jan W. Gratama,Yvonne J M Oussoren,Willemijn J Scholten,J. Slomp,Alexander N Snel,Marie-Christiane Vekemans,Bob Löwenberg,Gert J. Ossenkoppele,Gerrit Jan Schuurhuis +35 more
TL;DR: The value of immunophenotypically assessed MRD in the context of a multicenter clinical trial in adult AML is established, based not only on risk estimation assessed at diagnosis but also on MRD as a therapy-dependent prognostic factor.
Journal ArticleDOI
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich,Volker Diehl,Helen Görgen,Thomas Pabst,Jana Markova,Jürgen Debus,Anthony D. Ho,Bernd Dörken,Andreas Rank,Anca-Ligia Grosu,Thomas Wiegel,Johann H. Karstens,Richard Greil,Normann Willich,Heinz Schmidberger,Hartmut Döhner,Peter Borchmann,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Andreas Engert +19 more
TL;DR: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.
Journal ArticleDOI
Cytarabine dose for acute myeloid leukemia.
Bob Löwenberg,Thomas Pabst,Edo Vellenga,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Bart J. Biemond,Alois Gratwohl,Georgine E. de Greef,Leo F. Verdonck,Martijn R. Schaafsma,Michael Gregor,Matthias Theobald,Urs Schanz,Johan Maertens,Gert J. Ossenkoppele +17 more
TL;DR: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level.